Article

Anesthetic Nasal Solution Granted FDA Approval

The nasal solution is a local anesthetic indicated for the introduction of local anesthesia of the mucous membranes for diagnostic procedures and surgeries.

Officials with the FDA have approved Lannett Company's New Drug Application for cocaine hydrochloride (HCI) nasal solution, 4% (Numbrino).

The nasal solution is a local anesthetic indicated for mucous membranes with diagnostic procedures and surgeries, on or through the naval cavities of adults, according to Lannett.

The NDA submission was supported by a pair of phase 3, placebo-controlled, multicenter studies in several patients, as well as a phase 1 pharmacokinetic study.

REFERENCE

Lannett announces FDA approval of NDA for branded anesthetic product, cocaine hydrochloride nasal solution, 4% [news release]. Philadelphia, PA; Lannett: January 13, 2020. https://lannett.investorroom.com/2020-01-13-Lannett-Announces-FDA-Approval-Of-NDA-For-Branded-Anesthetic-Product-Cocaine-Hydrochloride-Nasal-Solution-4. Accessed January 14, 2020.

Related Videos
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Hurricane Helene, Baxter plant, IV fluids shortage, health systems impact, injectable medicines, compounding solutions, patient care errors, clinical resources, operational consideration, fluid conservation, sterile water, temperature excursions, training considerations, patient safety, feedback request
Image Credit: © peopleimages.com - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards